Left bar

About Modigene

We are a biopharmaceutical company utilizing patented technology to develop longer-lasting, proprietary versions of already approved therapeutic proteins that currently generate billions in annual global sales.

CTP Competitive Advantages

The creation of a successful, non-toxic and non-immunogenic long-lasting therapeutic protein is a very "tricky" process. The more the modified protein looks like the authentic molecule, the less toxic it is, and the less immunogenic - however this protein will break apart as quickly as the authentic molecule.

The Story Of FSH-CTP

Follicle Stimulating Hormone ("FSH") is a hormone that naturally exists in females. Women who have fertility problems may get supplemental FSH to increase the likelihood of pregnancy. Women have to be injected daily, for seven days, with FSH, at around ovulation time. The FSH market is significant, with more than $1.0 billion of sales in 2005.
Latest News
3/31/2008 Globes: Phillip Frost leads investment in another Israeli biomed co.
The Frost Group LLC, controlled by Dr. Phillip Frost, is making its second investment in Israel, leading a $12 million in ModiGene Inc.
MODIGENE ANNOUNCES CLOSING OF $12 MILLION FINANCING BY MEMBERS OF THE FROST GROUP
Financing Includes Equity Investment and Line of Credit
3/5/2008 Modigene Names Frost Chairman, South Florida Business Journal
Miami entrepreneur Dr. Phillip Frost has been named chairman of Modigene, an Israeli company he and some associates bought a large stake in last May.
3/5/2008 MODIGENE ANNOUNCES APPOINTMENT OF DR. PHILLIP FROST AS CHAIRMAN OF ITS BOARD OF DIRECTORS
11/27/2007 MODIGENE AWARDED ISRAELI GOVERNMENT GRANT TO SUPPORT DEVELOPMENT OF ITS LONGER-ACTING HUMAN GROWTH HORMONE
$10 Million hGH-CTP Development Program Has Been Approved For Funding Through A Special Grant From The Israeli Office of The Chief Scientist
10/5/2007 Layers Of Frost, FloridaTrend.com, by Mike Vogel
"My approch is the classical one where the harder I work the luckier I get", Dr. Phillip Frost
9/24/2007 STUDY PUBLISHED IN ENDOCRINOLOGY REPORTS POTENTIAL OF MODIGENE TECHNOLOGY TO EXTEND DURATION OF PROTEIN DRUGS
7/16/2007 MODIGENE PREPARES TO ADVANCE ITS LONG-ACTING HUMAN GROWTH HORMONE TOWARD CLINICAL TRIALS VIA GMP MANUFACTURING AGREEMENT
7/2/2007 KEY TRIALS OF ORGANON’S LONG-ACTING FERTILITY DRUG USING MODIGENE’S CTP TECHNOLOGY ACHIEVE CLINICAL TRIAL MILESTONE
6/20/2007 Technology for long-acting proteins here to stay, InPharna Technologist.com, by Katrina Megget
Modigene's technology however, takes a mother nature approach to finding a long-lasting solution. This would be a stark therapeutic contrast to the three-plus a week injections required with the currently marketed drugs.
6/20/2007 BioCheck: Modigene: A New Biotech With Impressive Genes, StockHouse Editorials, by Leon Hamerling and J. Paul
Combining Phil Frost's track record with all the factors we've touched on above, Modigene clearly is one of the new crop of biotech companies going public that investors should be aware of.
5/15/2007 Ex-IVAX chief Frost invests in firm, MiamiHerald.com, by John Dorschner
Physician-entrepreneur Phillip Frost is on the move again, once again investing in a small bulletin board entity.
בניית אתריםWeb Building
 Copyright 2006 © Modigene Inc. All rights reserved